Specialised Therapeutics Australia: New drug to fight hospital superbug infection
STA Chief Executive Officer Mr Carlo Montagner said: “CDI presents a serious bacterial health threat and current CDI treatment options available in Australia and New Zealand are limited. Our license of DIFICID provides a great opportunity to bring a much-needed new therapy to patients.”
DIFICID is the first in a new class of macrolide antibiotics, which are minimally absorbed by the bloodstream and have been shown to fight the CDI infection while leaving healthy gut flora untouched. DIFICID works by inhibiting the bacterial enzyme RNA polymerase, resulting in the death of C. difficile bacteria. Patients typically develop CDI when using broad spectrum antibiotics, which disrupt normal gut flora and enable the infection to take hold.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.